Immunomic Therapeutics, Inc.
↗Rockville, Maryland, United States
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical-stage biotechnology company pioneering the development of vaccines through its proprietary UNiversal Intracellular Targeted Expression (UNITE®) platform. The company focuses on developing DNA and RNA-based vaccines that leverage lysosomal targeting technology to generate broad immune responses across multiple therapeutic areas. The UNITE® platform is designed to engineer chimeric proteins that direct antigen-presenting cells to present antigens through a targeted pathway, driving robust immune responses with applications in oncology, infectious disease, allergy, and animal health.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology biotech | Vaccine therapeutics | Nucleic acid immunotherapy
SIZE & FINANCIALS
Employees:51-200
Founded:2005
Ownership:subsidiary
Status:operating
FUNDING
Stage:Series A
Total Raised:$97.9M
Investors:HLB (Holding Companies), Life Sciences Greenhouse of Pennsylvania, Brainchild Holdings, Keiretsu Forum Northwest, Mid Atlantic Bio Angels, Minority Angel Investor Network, National Institute for Allergy and Infectious Disease, Astellas Pharma
PIPELINE
Stage:Phase 1 - Phase 2
Lead Drug Stage:Phase 1/2
Modalities:Plasmid DNA vaccines, Self-amplifying RNA (saRNA), Nucleic acid vaccines
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:HLB Group (South Korea)
Acquired By:HLB Group (South Korea) (2019-01-01)
Key Partnerships:Astellas Pharma, University of Florida, Dana Farber Cancer Institute, University of Washington / Fred Hutchinson Cancer Research Center, Johns Hopkins University, Lineage Cell Therapeutics
COMPETITION
Position:Emerging|Niche Player
Competitors:Altimmune, Profectus BioSciences, Vaxart, Candel Therapeutics, Elicio Therapeutics, Moderna, BeiGene, Jazz Pharmaceuticals +1 more
LEADERSHIP
Key Executives:
Dong-Gun Kim - Chief Executive Officer & Board Chair
Teri Heiland - Chief Scientific Officer
Cara Sholter - Vice President, Quality Assurance
Scientific Founders:Dr. William G. Hearl, Dr. Teri Heiland
Board Members:Dong-Gun Kim (CEO & Chair), Yang Gon Jin (Chairman of HLB Board), Robert V. Ahlgren (30+ years in laboratory supply and diagnostics), Ki Hong Ahn (CEO of HLB Therapeutics), James W. Wishart, Alex S. Kim (CEO of Elevar Therapeutics)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immunomic Therapeutics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.